$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000106282214000031 Filed on August 07, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$419.0K	$676.0K	$214.0K
YoY Change	76.05%	215.89%	7.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.500M	$5.000M	$4.700M
YoY Change	-4.26%	6.38%	-7.84%
% of Gross Profit
Research & Development	$24.11M	$21.19M	$23.69M
YoY Change	-5.09%	-10.57%	22.41%
% of Gross Profit
Depreciation & Amortization	$500.0K	$600.0K	$800.0K
YoY Change	-16.67%	-25.0%	-27.27%
% of Gross Profit
Operating Expenses	$40.76M	$26.79M	$28.84M
YoY Change	29.57%	-7.11%	12.3%
Operating Profit	-$40.34M	-$26.11M	-$28.62M
YoY Change	29.22%	-8.78%	12.34%
Interest Expense	$449.0K	$455.0K	$496.0K
YoY Change	-8.74%	-8.27%	-6.42%
% of Operating Profit
Other Income/Expense, Net	$287.0K	$538.0K	-$4.000K
YoY Change	2509.09%	-13550.0%	-119.05%
Pretax Income	-$40.50M	-$26.00M	-$29.10M
YoY Change	27.76%	-10.65%	12.36%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$40.50M	-$26.03M	-$29.08M
YoY Change	27.92%	-10.5%	12.14%
Net Earnings / Revenue	-9665.39%	-3850.3%	-13588.79%
Basic Earnings Per Share
Diluted Earnings Per Share	-$551.0K	-$353.7K	-$397.0K
COMMON SHARES
Basic Shares Outstanding	514.8M shares	514.9M shares	513.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$57.40M	$78.60M	$174.9M
YoY Change	-61.94%	-55.06%	-24.32%
Cash & Equivalents	$26.78M	$27.73M	$23.25M
Short-Term Investments	$30.70M	$50.90M	$151.7M
Other Short-Term Assets	$5.937M	$7.342M	$6.684M
YoY Change	-18.19%	9.84%	1.55%
Inventory
Prepaid Expenses
Receivables	$165.0K	$281.0K	$1.014M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$87.82M	$86.67M	$183.1M
YoY Change	-44.89%	-52.66%	-23.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.494M	$39.18M	$42.15M
YoY Change	-96.43%	-7.06%	-5.33%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$108.0K	$120.0K	$65.00K
YoY Change	-31.65%	84.62%	-58.6%
Total Long-Term Assets	$99.70M	$137.4M	$140.3M
YoY Change	-28.83%	-2.08%	-1.73%
TOTAL ASSETS
Total Short-Term Assets	$87.82M	$86.67M	$183.1M
Total Long-Term Assets	$99.70M	$137.4M	$140.3M
Total Assets	$187.5M	$224.1M	$323.4M
YoY Change	-37.38%	-30.71%	-15.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.741M	$8.350M	$6.281M
YoY Change	0.33%	32.94%	37.17%
Accrued Expenses	$13.13M	$10.89M	$11.32M
YoY Change	13.92%	-3.84%	-24.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.61M	$1.783M	$22.68M
YoY Change	1130.39%	-92.14%	1401.85%
Total Short-Term Liabilities	$44.27M	$21.90M	$40.90M
YoY Change	87.6%	-46.47%	89.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$19.26M	$0.00
YoY Change	-100.0%		-100.0%
Other Long-Term Liabilities	$34.01M	$34.82M	$35.26M
YoY Change	-9.06%	-1.23%	-40.52%
Total Long-Term Liabilities	$34.01M	$54.08M	$35.26M
YoY Change	-41.37%	53.38%	-56.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.27M	$21.90M	$40.90M
Total Long-Term Liabilities	$34.01M	$54.08M	$35.26M
Total Liabilities	$109.7M	$107.4M	$108.3M
YoY Change	-3.56%	-0.84%	-20.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.101B	-$1.061B	-$954.9M
YoY Change	11.63%	11.09%	12.95%
Common Stock	$516.0K	$516.0K	$514.0K
YoY Change	0.39%	0.39%	6.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.390M	$2.390M	$1.503M
YoY Change	59.02%	59.02%	138.57%
Treasury Stock Shares	1.281M shares	1.281M shares	814.0K shares
Shareholders Equity	$77.82M	$116.7M	$215.1M
YoY Change
Total Liabilities & Shareholders Equity	$187.5M	$224.1M	$323.4M
YoY Change	-37.38%	-30.71%	-15.13%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$40.50M	-$26.03M	-$29.08M
YoY Change	27.92%	-10.5%	12.14%
Depreciation, Depletion And Amortization	$500.0K	$600.0K	$800.0K
YoY Change	-16.67%	-25.0%	-27.27%
Cash From Operating Activities	-$21.20M	-$19.70M	-$21.10M
YoY Change	-11.3%	-6.64%	-4.09%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$400.0K
YoY Change	-100.0%	-100.0%	300.0%
Acquisitions
YoY Change
Other Investing Activities	$20.50M	$1.200M	$10.90M
YoY Change	0.0%	-88.99%	-59.48%
Cash From Investing Activities	$20.50M	$1.200M	$10.40M
YoY Change	0.99%	-88.46%	-61.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-300.0K	-400.0K	-300.0K
YoY Change		33.33%	50.0%
NET CHANGE
Cash From Operating Activities	-21.20M	-19.70M	-21.10M
Cash From Investing Activities	20.50M	1.200M	10.40M
Cash From Financing Activities	-300.0K	-400.0K	-300.0K
Net Change In Cash	-1.000M	-18.90M	-11.00M
YoY Change	-72.22%	71.82%	-334.04%
FREE CASH FLOW
Cash From Operating Activities	-$21.20M	-$19.70M	-$21.10M
Capital Expenditures	$0.00	$0.00	-$400.0K
Free Cash Flow	-$21.20M	-$19.70M	-$20.70M
YoY Change	-10.17%	-4.83%	-5.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9715000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8350000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	839000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4100000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	790000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	281000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7674000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4000000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10886000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	76945000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81945000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1179358000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1175108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3978000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4090000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2014Q2	us-gaap	Assets Assets	224064000	USD
CY2013Q4	us-gaap	Assets Assets	274160000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	134554000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	86667000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37499000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27725000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23254000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30423000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9774000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7169000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Contracts Revenue ContractsRevenue	799000	USD
	us-gaap	Contracts Revenue ContractsRevenue	495000	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	211000	USD
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	627000	USD
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	516000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26033000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29091000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55046000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56860000	USD
CY2014Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	877000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13405000	USD
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12679000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1618000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1198000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1741000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1590000	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	31661000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29920000	USD
CY2014Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29300000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27710000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	733000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4669000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10806000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5152000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8993000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2014Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4300000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	242000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2251000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2692000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-364000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-509000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	44000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	51000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	44000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-335000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2706000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	455000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	496000	USD
	us-gaap	Interest Expense InterestExpense	912000	USD
	us-gaap	Interest Expense InterestExpense	1002000	USD
	us-gaap	Interest Paid Net InterestPaidNet	896000	USD
	us-gaap	Interest Paid Net InterestPaidNet	962000	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	44000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	97000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20167000	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19255000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1299000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	103997000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	107396000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	274160000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	224064000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19294000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21896000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	49000	USD
	us-gaap	Licenses Revenue LicensesRevenue	154000	USD
CY2013Q2	us-gaap	Licenses Revenue LicensesRevenue	3000	USD
	us-gaap	Licenses Revenue LicensesRevenue	79000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1710000	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1783000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1591000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41791000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39533000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45403000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49974000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-29080000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-26028000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55054000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56863000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	26787000	USD
	us-gaap	Operating Expenses OperatingExpenses	57536000	USD
	us-gaap	Operating Expenses OperatingExpenses	54753000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	28838000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-28624000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56583000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26111000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54179000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	7342000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4636000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	144000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	120000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-11000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32386000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34821000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	534000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	620000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	887000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	873000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20651000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80954000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1238000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	347000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-27000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	60964000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	121623000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	102000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1517000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39177000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	773000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41362000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21187000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23692000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44019000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45140000	USD
CY2013Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q2	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q2	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	5400000	USD
CY2014Q2	us-gaap	Restructuring Reserve RestructuringReserve	1600000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1060821000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1003958000	USD
CY2013Q2	us-gaap	Revenues Revenues	214000	USD
CY2014Q2	us-gaap	Revenues Revenues	676000	USD
	us-gaap	Revenues Revenues	574000	USD
	us-gaap	Revenues Revenues	953000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q2	us-gaap	Secured Debt SecuredDebt	21000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4090000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3978000	USD
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	51319000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	91629000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	347000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	162000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	116668000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	170163000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170163000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116668000	USD
CY2013Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	215084000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	266678000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	814000	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1281000	shares
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2390000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1503000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	887000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	873000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	8000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	513083000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	514623000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	512757000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	514291000	shares
CY2014Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	448000	USD
CY2013Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	477000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1741000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1590000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
	lxrx	Restructuring Cost Other Costs High Endof Range RestructuringCostOtherCostsHighEndofRange	600000	USD
	lxrx	Restructuring Cost Other Costs Low Endof Range RestructuringCostOtherCostsLowEndofRange	300000	USD
	lxrx	Restructuring Cost Severance Costs RestructuringCostSeveranceCosts	5400000	USD
	lxrx	Restructuring Cost Total Expected Cost High Endof Range RestructuringCostTotalExpectedCostHighEndofRange	6000000	USD
	lxrx	Restructuring Cost Total Expected Cost Low Endof Range RestructuringCostTotalExpectedCostLowEndofRange	5700000	USD
	lxrx	Restructuringand Related Costs Cost Incurredto Date Generaland Administrative RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative	600000	USD
	lxrx	Restructuringand Related Costs Cost Incurredto Date Researchand Development RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment	4800000	USD
	lxrx	Restructuringand Related Costs Cost Incurredto Date Stockbased Compensation RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation	100000	USD
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	102560	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	1.56
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1626000	USD
CY2014Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	900000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1692000	USD
CY2013Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	847000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2352000	USD
CY2014Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	940000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2398000	USD
CY2013Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1022000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	514818527	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-14-000031-index-headers.html	Edgar Link	pending
0001062822-14-000031-index.html	Edgar Link	pending
0001062822-14-000031.txt	Edgar Link	pending
0001062822-14-000031-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20140630.xml	Edgar Link	completed
lxrx-20140630.xsd	Edgar Link	pending
lxrx-20140630_cal.xml	Edgar Link	unprocessable
lxrx-20140630_def.xml	Edgar Link	unprocessable
lxrx-20140630_lab.xml	Edgar Link	unprocessable
lxrx-20140630_pre.xml	Edgar Link	unprocessable
lxrx630201410-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2014 Q3 Form 10-Q Financial Statement

#000106282214000031 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2014 Q3 Form 10-Q Financial Statement

#000106282214000031 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx